drugset / Trial / NCT02938962

Intravenous vs. Topical Tranexamic Acid in Revision THA (VITALITY-X)

NCT02938962

Phase 4 Unknown 160 enrolled Mount Sinai Hospital, Canada
RandomizedParallel-groupTriple-blindPrevention

Summary

The objective of this study is to evaluate and compare the effects of intravenous and topical administration of tranexamic acid during revision hip arthroplasty on blood loss, allogenic blood transfusion rates, length of hospital stay and perioperative complications.

Timeline

Start
2016-10
Primary completion
2018-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tranexamic Acid Small molecule 20 mg/kg Intravenous
Comparator Tranexamic Acid Small molecule 3 g Intravenous

Indications

No indication recorded.